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Abstract
Advanced Glycation Endproducts (AGEs) are greatly elevated in bone extracellular matrix of patients with 
Diabetes mellitus, and this has been associated with the increased incidence of fractures observed in these patients. 
AGEs affect the homeostasis of bone cells such as osteoblasts and osteoclasts. Bisphosphonates are first-line 
anti-osteoporotic drugs that principally exert their effects by inhibiting osteoclastic activity. However, the effect of 
bisphosphonate treatment on bone quality in patients with Diabetes is uncertain. In the present work we have 
evaluated the action of AGEs (50-200 μg/ml), with or without Alendronate (10-8-10-4M), on osteoclastogenesis 
induced by co-cultures of Raw 264.7 macrophages and UMR106 osteoblasts. We determined the effects of different 
culture conditions on osteoclastic recruitment, tartrate-resistant acid phosphatase (TRAP) activity and expression of 
RAGE (receptor for AGEs); and on the osteoblastic expression of RANK ligand (RANKL). AGEs and Alendronate 
inhibited the recruitment and TRAP activity of osteoclasts, with an additive effect of both agents at high concentrations 
of Alendronate. While AGEs prevented the early and late stages of osteoclastogenesis, Alendronate (alone or in 
co-incubation with AGEs) only inhibited its later stages. In addition, both AGEs and Alendronate increased the 
osteoclastic expression of RAGE and decreased the osteoblastic expression of RANKL, correlating closely with 
their inhibition of osteoclastogenesis. If these in vitro results can be extrapolated to a clinical setting, they may be 
indicating a potentiation of the anti-resorptive effects of Alendronate in the context of bone extracellular matrix with 
excess accumulation of AGEs, as might occur in a patient with Diabetes mellitus.
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Introduction
Advanced Glycation Endproducts (AGEs) are post-translational, 
non-enzymatic and irreversible modifications of proteins that 
can alter their bioactivity. AGEs have been strongly implicated in 
the pathogenesis of the more prevalent chronic complications of 
Diabetes mellitus such as atherosclerosis, nephropathy, retinopathy 
and neuropathy [1]. More recently, their role in diabetic osteopathy 
has begun to be analyzed. Levels of AGEs are greatly elevated in the 
bone extracellular matrix of patients with Diabetes mellitus, and this 
accumulation of AGEs has been associated with the increased fracture 
rates observed in patients with both types of Diabetes [2,3]. In addition, 
AGEs have been found to accumulate with physiological ageing in 
various tissues including bone, and so they have also been implicated 
in the development of osteoporosis in elderly non-diabetic individuals 
[4,5].
AGEs can exert deleterious effects on bone-derived cells: they 
decrease the osteogenic potential of bone marrow mesenchymal cells 
[6] and inhibit the bone-forming capacity of osteoblasts [7]. Two 
apparently contradictory studies also indicate that AGEs can directly 
regulate osteoclastic activity. One study shows that short-term exposure 
to AGEs can activate osteoclast-mediated bone resorption [8], whereas 
the other study shows the opposite effect albeit after a longer exposure 
to extracellular AGEs [9].
Many cellular effects of AGEs occur due to the interaction of 
these moieties with specific receptors such as RAGE. This receptor is 
expressed in osteoblasts [10] and osteoclasts [9], and its occupation by 
AGEs has been postulated to reduce bone remodelling and collagen 
turnover, thus facilitating the accumulation of more AGEs in bone 
extracellular matrix [9] that could contribute to the decrease in bone 
quality associated with ageing and Diabetes mellitus.
Osteoclasts arise from hematopoietic stem cells that, in the presence 
of the receptor activator of nuclear factor kB (RANK) ligand (RANKL) 
and macrophage-colony stimulating factor, undergo differentiation 
and fusion resulting in large multinucleated cells characterized by 
expression of a series of osteoclast markers, such as tartrate-resistant 
acid phosphatase (TRAP) [11]. This enzyme, in the context of bone, 
is a specific and sensitive osteoclastic marker permitting accurate 
assessment of the abundance of this cell type. RANKL is expressed on 
the surface of osteoblast-lineage cells, and functions by interacting with 
its receptor RANK on osteoclast precursors [12].
Bisphosphonates (BP) are first-line anti-osteoporotic drugs that 
mainly exert their effects by inhibiting osteoclastic recruitment and 
activity, and secondarily by increasing osteoblast bone-forming 
activity. Part of these actions may take place by reduction of RANKL 
expression by osteoblasts and/or bone marrow stromal cells, which in 
turn decreases osteoclastogenesis and bone resorption [13].
Although the use of BP such as Alendronate has been 
recommended by some authors for treatment of diabetic osteopathy, 
this could potentially pose a problem since Diabetes mellitus is 
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generally associated with low bone turnover [14]. Thus in this context, 
BP treatment could further reduce bone remodelling, increase AGEs 
accumulation and decrease bone quality. In an attempt to address 
this issue, we previously evaluated the combined in vitro actions of 
Alendronate and AGEs on bone-forming cells, and demonstrated that 
Alendronate is able to prevent the anti-osteogenic and pro-apoptotic 
effects of AGEs on osteoblasts [15]. Additionally, the results of two 
recent clinical studies support the use of this BP in diabetic patients: 
Keegan et al. reported that a 3-year treatment with Alendronate was 
associated with increased BMD in older women with type 2 Diabetes 
mellitus [16], whereas Ikeda and Iwata showed that treatment with 
this BP for 5 years inhibited the decrease in radial BMD induced by 
Diabetes [17]. However, there is still a concern regarding the effects of 
BP treatment on bone quality in diabetic patients, and this can only be 
addressed by evaluating fracture incidence in controlled studies.
Although the mechanisms of action of BP on osteoclasts are 
known with precision [18], their effect on this cell type in the presence 
of excess AGEs is not. The main hypothesis of our present study was 
that the inhibitory effect of Alendronate on osteoclastogenesis could be 
potentiated in the presence of AGEs. In order to test this hypothesis, 
we investigated the combined effect of AGEs and Alendronate on the 
recruitment and differentiation of osteoclastic cells obtained by co-
culture, and on the expression and sub-cellular distribution of RANKL 
and RAGE.
Materials and Methods
Materials
Alendronate [1-hydroxy-3-aminobutylidene-1,1-bisphosphonic 
acid] was provided by Elea Laboratories (Argentina); Dulbecco´s 
modified Eagle´s medium (DMEM), trypsin-EDTA and foetal 
bovine serum (FBS) were obtained from Gibco (Invitrogen, Buenos 
Aires, Argentina). Tissue culture disposable material was from Nunc 
(Tecnolab, Buenos Aires, Argentina). Centricon 10 kDa cutoff filter 
cartridges were purchased from Amicon Inc. (Beverly, Mass., USA). 
Bovine serum albumin, D-glycolaldehyde, Triton X-100 were obtained 
from Sigma-Aldrich (Buenos Aires, Argentina). Goat polyclonal anti-
RAGE and Rabbit polyclonal anti- RANKL antibodies were from Santa 
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Cellular tartrate 
resistant acid phosphatase (TRAP) activity was measured using the 
Leukocyte Acid Phosphatase kit (Sigma-Aldrich). All other chemicals 
and reagents were purchased from commercial sources and were of 
analytical grade.
Preparation of advanced glycation endproducts
Advanced glycation endproducts-modified (AGEs) bovine serum 
albumin (BSA) was prepared by incubation of 10 mg/ml BSA with 33 
mM D-glycolaldehyde in 150 mM phosphate-buffered saline pH 7.4 
at 37°C for 3 days under sterile conditions [19]. D-glycolaldehyde 
was used as the glycating sugar instead of glucose to speed up non-
enzymatic glycosylation. Control BSA was incubated in the same 
conditions without sugar. The unincorporated sugar was removed 
by centrifugation/filtration with Centricon filter cartridges. The 
formation of AGEs was assessed with a LUMEX Fluorat®-02-Panorama 
spectrofluorometer (St. Petersburg, Russia), by their characteristic 
fluorescence-emission maximum at 420 nm upon excitation at 340 nm. 
The estimated level of AGEs obtained in this in vitro incubation was 
18.5 % relative fluorescence intensity/mg protein, in contrast to 3.2 % 
for control BSA.
Cellular cultures
Co-culture of raw 264.7 and UMR106 cells: As a model system 
of osteoclastogenesis, we used a co-culture of the Raw 264.7 a murine 
monocyte/macrophage cell line with UMR106 rat osteosarcoma cells 
[20]. For different experiments, Raw 264.7 and UMR106 were co-
cultured on 6 or 24-well plates in DMEM supplemented with penicillin 
(100 UI/ml), streptomycin (100 μg/ml) and 10% FBS, with or without 
different doses of AGEs (50, 100, 200 µg/ ml) and/or Alendronate (10-
8M, 10-7M, 10-6M, 10-5M, 10-4M). The culture medium was replaced 
every 48 h. Co-cultures were grown for 8 days.
Osteoblast cultures: The UMR106 rat osteosarcoma-derived cell 
line has been shown to conserve certain characteristics of differentiated 
osteoblastic phenotype [21]. In order to assess RANKL expression in 
UMR106 osteoblasts, cells were seeded on 6-well plates and incubated 
in DMEM with different doses of BSA or AGEs, with or without 
Alendronate, for the periods of time indicated in the legends of figures. 
At the end of the culture period, the monolayer was evaluated by 
indirect immunofluorescence to determine RANKL expression.
Estimation of TRAP activity 
Co-cultures grown in 24-well plates and submitted to different 
experimental conditions were washed with PBS and solubilized in 0.1% 
Triton X-100. An aliquot of the total cell extract was used to assess 
TRAP activity. For this, each aliquot was incubated in the reaction 
buffer (412 mM acetic acid, 0.209% Triton X-100, 412 mM NaCl, 4.12 
mM EDTA, 10.6 mM ascorbic acid, 10.1mM 4-nitrophenylphosphate, 
41.6mM Na2tartrate at pH: 5.5) at 37°C for 1 hour, after which the 
reaction was stopped with 100 µl of 300 mM NaOH and the product 
measured at 405 nm [9]. Another aliquot of each extract was used 
for protein determination by Bradford’s technique [22]. Results are 
expressed as TRAP specific activity (nmol p-NP/ mg protein x min).
Quantitation of the development of multinucleated giant 
cells
Co-cultures grown in 6-well plates and submitted to different 
experimental conditions were washed with PBS, fixed with methanol 
for 5 min and stained with Giemsa for 10 min. After washing, cells were 
observed under a light microscope. The number of multinucleated 
giant cells (> 3 nuclei/cell) was then counted in 50 fields per well. In 
some experiments, co-cultures were stained with TRAP cytochemistry 
to confirm the positivity of multinucleated cells for this osteoclast-
specific enzymatic activity.
Expression of RAGE and RANKL by immunofluorescence 
analysis
Cells grown on coverslips in 6-well plates were washed in cold 
PBS, fixed with 4% paraformaldehyde in PBS (10 minutes at room 
temperature), and permeabilized with methanol for 4 minutes at –20ºC 
[23]. Nonspecific binding sites were blocked with 1% BSA in PBS for 2 
hours. Cells (co-cultures or osteoblasts) were then incubated with anti-
RAGE or anti-RANKL antibody (1:300 in blocking buffer) overnight at 
4ºC. After washing, cells were exposed to a FITC-conjugated secondary 
antibody (1:200) for 1 hour at room temperature. Coverslips were 
mounted in PBS-glycerol and observed with a fluorescence confocal 
Leica TSC SP5 AOBS microscope for visualisation of sub-cellular 
distribution for each specific protein. Images were analysed using 
Image J program.
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Statistical analysis
The results are expressed as the mean ± S.E.M. and were obtained 
from three separate experiments performed in triplicate. Differences 
between groups were assessed by Oneway ANOVA with Tukey post-
hoc test. For non-normally distributed data, non-parametrical Kruskal 
Wallis with Dunn post-hoc test was performed using GraphPad in 
Stat version 3.00 (Graph Pad Software, San Diego, California, USA). A 
p-value < 0.05 was considered statistically significant.
Results
Effect of AGEs and alendronate on osteoclast recruitment 
and differentiation
To evaluate the possible action of AGEs and Alendronate on 
osteoclastogenesis, we used a co-culture model with Raw 264.7 
macrophages and UMR106 osteoblastic cells, evaluating TRAP activity 
after 8 days. As can be seen in Figure 1, this co-culture induced the 
formation of giant multinucleated TRAP (+) osteoclasts. When TRAP 
enzymatic activity was quantified in co-culture lysates as described in 
Materials and methods, this marker of osteoclast differentiation was 
decreased after exposure to AGEs in a dose-dependent manner (10-30% 
reduction versus control BSA) (Figure 2A). We also investigated the 
effect of different doses of Alendronate (included in the culture media 
together with either BSA or AGEs) on osteoclastic differentiation. For 
these experiments we chose a dose of 100 µg / ml of AGEs, which on its 
own reduces TRAP activity by 13% (Figure 2A). As can be seen in Figure 
2B, low doses of Alendronate (10-8M-10-6M) co-incubated with BSA 
induced a significant decrease in TRAP activity (about 10% reduction 
versus BSA alone). However when these low doses of Alendronate were 
co-incubated with AGEs, TRAP activity showed no difference versus 
AGEs alone. High levels of Alendronate (10-5M-10-4M) also reduced 
TRAP activity, although in this case both when co-incubated with BSA 
(25% decrease versus BSA alone) or with AGEs (17% decrease versus 
AGEs alone).
AGEs and Alendronate additionally affected the recruitment (i.e., 
number) of multinucleated cells. As can be seen in Figure 3B, the 
average number of osteoclasts per field was significantly inhibited 
by the presence of AGEs in the culture media (45% reduction versus 
BSA alone). Figure 3A shows representative fields of TRAP-stained 
macrophage/osteoblast co-cultures, incubated either with BSA (left) or 
with AGEs (right), in which inhibition of the number of multinucleated 
cells by AGEs can be observed. Alendronate, when co-incubated with 
BSA, also induced a significant and dose-dependent decrease in the 
number of osteoclasts. However when Alendronate was co-incubated 
with AGEs, only high doses (10-5M) of this BP induced an additional 
effect on the inhibition of osteoclastic recruitment (16% decrease 
versus AGEs alone), whereas low doses did not. 
AGEs and alendronate inhibit different stages of osteoclastic 
induction
To evaluate whether AGEs and/or high doses (10-5 M) of 
Alendronate preferentially affect early or late osteoclastogenesis, these 
agents were added to the co-culture at different time points. As can 
be seen in Figure 4, AGEs significantly inhibited osteoclastic TRAP 
activity at all time points. On the other hand, high-dose Alendronate 
only appears to decrease osteoclastogenesis in its later stages since its 
inclusion in the culture media during the first four days of co-culture 
did not induce an inhibition of TRAP activity, both when co-incubated 
with BSA or with AGEs. However, the addition of Alendronate to 
the culture media during the last four days of co-culture significantly 
inhibited osteoclastic TRAP activity (25% decrease versus BSA alone, 
and 30% reduction versus AGEs alone).
AGEs and alendronate modulate RAGE expression in 
osteoclastic cells
The effect of AGEs and/or Alendronate on RAGE expression was 
evaluated by indirect immunofluorescence. The inclusion of AGEs in 
the co-culture media (Figure 5Ad) induced a significant increase in 
osteoclastic RAGE-associated fluorescence (152% versus BSA alone) 
Figure 1: Environmental-Scanning Electron Microscopy (E-SEM) images 
of co-cultures of Raw 264.7 macrophages and UMR-106 osteoblastic cells. 
Left: Image showing a dark giant cell (osteoclast) and smaller high-contrast 
Raw 264.7 cells (1400x). Middle: Magnification of the same image showing 
the osteoclast (3000x). Right: Osteoclast stained by TRAP cytochemistry (Obj. 
40x).
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Figure 2: Effect of AGEs and/or alendronate on osteoclastogenesis. (A) UMR-
106 osteoblastic cells and Raw 264.7 macrophages were co-cultured for 4 days 
until formation of multinucleated cells. They were then incubated with different 
doses (50 µg/ml, 100 µg/ml or 200 µg/ml) of BSA or AGEs for an additional 4 
days. TRAP activity was determined in cell lysates by a colorimetric method. 
Results are expressed as % of basal (BSA alone), and are shown as the mean 
± S.E.M. (* p<0.05, ** p<0.01). (B) UMR-106 osteoblastic cells and Raw 264.7 
macrophages were co-cultured for 4 days until formation of multinucleated 
cells. They were then incubated for an additional 4 days with 100 µg/ml of BSA 
or AGEs, and/or different doses of alendronate (10-8M - 10-4M). TRAP activity 
was determined in cell lysates by a colorimetric method. Results are expressed 
as % of basal (BSA alone), and are shown as the mean ± S.E.M. (* p<0.05, ** 
p<0.001 versus BSA alone) (# p<0.001 versus AGEs alone)
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(Figure 5B). Similarly, inclusion of low doses (10-8M) of Alendronate 
plus BSA (Figure 5Ab) induced a significant increase in RAGE 
expression (130% versus BSA alone). However, high doses (10-5M) 
of Alendronate plus BSA did not alter the osteoclastic expression of 
RAGE (Figure 5Ac and B). 
On the other hand, although the AGEs-induced up-regulation 
of RAGE was unmodified by low doses of Alendronate (Figure 5Ae 
and B), it was completely blocked in the presence of high doses of 
Alendronate (Figure 5Af and B).
AGEs and alendronate modulate RANKL expression in 
osteoblastic cells
We next investigated the modulation of RANKL expression (by 
immunofluorescence) in osteoblasts cultured with AGEs and/or 
Alendronate, as a possible mechanism by which these agents might 
be regulating osteoclastic recruitment and differentiation. As can be 
seen in Figure 6, 100 µg / ml AGEs significantly inhibited osteoblastic 
RANKL expression (50% versus BSA alone). Similarly, Alendronate 
(10-8M-10-5M) dose-dependently inhibited osteoblastic RANKL-
associated fluorescence (65-47% versus BSA alone). However, when 
osteoblasts were co-incubated with AGEs and Alendronate (10-8M-10-
5M) no further inhibition of RANKL expression was observed (59-45% 
versus BSA alone).
Discussion 
N-containing bisphosphonates (BP) are one of the most widely 
used classes of anti-osteoporotic drugs. Although their primary action 
is to inhibit osteoclastic functionality and survival, they have also been 
found to promote osteoblastic development and osteogenic potential. 
At present the prescription of BP in patients with diabetic osteopathy 
has not been firmly recommended, since results of clinical studies 
tend to be contradictory [24,25,14]. These contradictions may be 
due to different causes, and since AGEs are greatly increased in the 
extracellular matrix of bone tissue in patients with poorly compensated 
Diabetes mellitus [2], one of these causes could be possible interactions 
between the effects of BP and AGEs on bone cells.
Although the mechanisms of action of BP on osteoclasts have 
been firmly established, the effect of AGEs on this cell type has been 
poorly defined and published reports are controversial [8,9]. Using 
unfractionated mouse bone marrow cultures that included osteoclasts 
among other cell types, Miyata and co-workers found an increase in 
resorption pits (but not in osteoclast number) when the cultures were 
incubated for 4 days on AGEs-modified dentin slices. In the other 
published report on this issue, Valcourt et al. found that both human 
and rabbit osteoclasts, when cultured on ivory slices modified with 
pentosidine (an established AGEs structure), transiently increased 
their resorptive action after 3 days but were greatly inhibited if cultures 
were extended to 8 days [9].
In our present study with macrophage/osteoblast co-cultures, we 
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Figure 3:  Effect of AGEs and/or alendronate on osteoclastic recruitment. (A) 
The photographs show representative fields of TRAP-stained macrophage/
osteoblast co-cultures, incubated either with BSA (left) or with AGEs (right). 
Exposure to AGEs clearly decreases the abundance of multi-nucleated TRAP 
(+) osteoclasts. (B) Average number of osteoclasts per field in different culture 
conditions. UMR-106 osteoblastic cells and Raw 264.7 macrophages were 
co-cultured on coverslips placed in 6-well plates for 4 days until formation of 
multinucleated cells. They were then incubated for an additional 4 days with 
100 µg/ml of BSA or AGEs, and/or different doses of alendronate (10-8M or 10-
5M). Cell monolayers were then fixed, stained with Giemsa, mounted on slides 
and cells with 3 or more nuclei in 50 fields at 400x were counted and averaged 
per field. Results are shown as the mean ± S.E.M. (* p<0.05, ** p<0.001 versus 
BSA alone) (# p<0.01 versus AGEs alone)
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Figure 4: AGEs and alendronate inhibit different stages of osteoclastogenesis. 
Raw 264.7 macrophages and UMR106 osteoblastic cells were co-cultured 
in 6-well plates. BSA or AGEs (100 µg/ml) and/or alendronate (10-5M) were 
added at different time points: a - from the beginning to the end of an 8-day 
co-culture; b - from the beginning to the end of a 4-day co-culture; and c – from 
day 4 to 8 of an 8-day coculture. At the end of all incubations, TRAP activity 
was determined cell lysates by a colorimetric assay. Results are expressed 
as % of basal (BSA alone for each time point), and are shown as the mean ± 
S.E.M. (* p<0.05).
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have found that soluble extracellular AGEs dose-dependently inhibit 
osteoclast number and TRAP activity, in both the early (4 days) 
and later (8 days) stages of osteoclastogenesis. Our results for 8-day 
cultures agree with those of Valcourt et al. the differences observed in 
the early stages of osteoclast induction could be due to the fact that we 
used soluble AGEs in the culture media instead of growing cells on an 
AGEs-modified mineralized substratum [9]. 
In further experiments we set out to evaluate the effect on osteoclastic 
induction and TRAP activity, of different doses of the N-containing 
BP Alendronate alone or in combination with soluble AGEs. On its 
own, Alendronate inhibited both parameters of osteoclastogenesis. 
This was observed both at low doses of the BP (10-8M-10-6M, such as 
might be expected in the extracellular fluid of a patient treated with 
Alendronate) and at high doses of the BP (10-5M-10-4M, similar to the 
concentration that can be attained in resorption pits). We also found 
that Alendronate inhibited osteoclastogenesis in its later stages, but not 
in its early stages. When we co-incubated Alendronate with AGEs we 
found that this BP was able to potentiate the inhibition of osteoclast 
induction by AGEs, although only at high doses of Alendronate and 
in the later stages of osteoclastogenesis. However, these are exactly the 
conditions that would be expected in the resorption pits of a patient 
with Diabetes who is treated with Alendronate, thus theoretically 
inducing an even greater inhibition of their associated osteoclasts.
Diverse actions of AGEs can be mediated by specific cell-surface 
receptors such as RAGE. This protein is expressed in many cell 
types, and bone cells such as osteoblasts [10] and osteoclasts [9] are 
no exception. Additionally, AGEs-RAGE interaction has been found 
to directly modulate osteoclastic recruitment and function [26]. 
Based on these observations, in the present study we evaluated by 
immunofluorescence whether exposure to AGEs and/or Alendronate 
could induce changes in osteoclastic RAGE expression. As previously 
described by other authors, incubation with AGEs alone induced an up-
regulation of RAGE in this cell type. Low-dose Alendronate on its own 
also increased RAGE expression, but when co-incubated with AGEs 
it did not induce further changes in RAGE-associated fluorescence. 
High-dose Alendronate alone did not modify the expression of RAGE 
in osteoclasts, although when this dose of BP was co-incubated with 
AGEs it completely prevented the up-regulation of RAGE induced by 
AGEs. 
Altogether, our present results suggest that the inhibitory effects 
of low-dose Alendronate on osteoclastogenesis might be partially 
mediated by changes in the expression of RAGE. On the other hand and 
in the presence of AGEs, high-dose Alendronate shows an inhibitory 
effect that does not depend on the modulation of RAGE expression.
An indirect mechanism by which AGEs and/or Alendronate could 
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Figure 5: AGEs and/or alendronate modulate RAGE expression in osteoclasts. 
(A) UMR-106 osteoblastic cells and Raw 264.7 macrophages were co-cultured 
for 4 days until formation of multinucleated cells. They were then incubated 
for an additional 4 days with 100 µg/ml BSA (a, b and c) or 100 µg/ml AGEs 
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10-5M alendronate (c and f). Expression of RAGE was evidenced by indirect 
immunofluorescence, as described in Materials and methods. (B) Whole-cell 
RAGE-associated immunofluorescence was quantified. Results are expressed 
as % of basal (BSA alone), and are shown as the mean ± S.E.M. (* p<0.05, ** 
p<0.001 versus BSA alone)
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65 ± 5  * 46 ± 5  **
45 ± 3 **
Figure 6: AGEs and/or alendronate modulate RANKL expression in 
osteoblasts. UMR-106 osteoblastic cells and Raw 264.7 macrophages were 
co-cultured for 4 days until formation of multinucleated cells. They were then 
incubated for an additional 4 days with 100 µg/ml BSA (a, b and c) or 100 µg/
ml AGEs (d, e and f), in the presence or absence of 10-8M alendronate (b and 
e) or 10-5M alendronate (c and f). Expression of RANKL was evidenced by 
indirect immunofluorescence, as described in Materials and methods. Inset 
table: whole-cell RANKL-associated immunofluorescence was quantified. 
Results are expressed as % of basal (BSA alone), and are shown as the mean 
± S.E.M. (* p<0.05, ** p<0.001 versus BSA alone).
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inhibit osteoclast recruitment and differentiation is by down-regulation 
of RANKL in osteoblasts/stromal cells. In experiments with UMR106 
osteoblastic cells, we found that the expression of RANKL was greatly 
reduced by AGEs alone or by Alendronate alone (in this case dose-
dependently), although co-incubation with both agents did not further 
inhibit RANKL. This decrease in osteoblastic RANKL expression 
closely correlated with the inhibition of osteoclastogenesis induced by 
AGEs and/or Alendronate. Other authors have found opposite effects 
of AGEs on the expression of RANKL, however for their study they used 
primary bone explant cultures that include different cell types [27]. On 
the other hand, our results for RANKL inhibition by Alendronate are 
in close agreement with other studies that report similar in vitro results 
for osteoblasts of human and rat origin [28-30]. Additionally, a recent 
clinical study has demonstrated that Alendronate treatment of women 
with post-menopausal osteoporosis reduces the expression of RANKL 
by osteoblasts and/or bone marrow stromal cells, which in turn can 
decrease osteoclastogenesis and bone resorption [13].
Diabetic osteopathy has been proposed to be an adynamic disease, 
caused by low bone turnover and/or formation. In a young growing 
subject with type 1 Diabetes, net low bone formation causes a decrease 
in bone mineral density (BMD) and a propensity to fractures. In 
patients with type 2 Diabetes, BMD tends to be normal or increased 
and this could be due to a decrease in bone remodeling frequency in 
an age group where there is usually a negative balance for individual 
remodeling cycles. Thus, BMD measurements in these patients can 
be misleading since decreased remodeling reduces bone quality at a 
micro-structural level, and this alone can increase fracture incidence. 
We have previously found that the accumulation of AGEs on 
a collagenous matrix decreases the integrin-mediated attachment, 
proliferation and bone-forming capacity of osteoblasts [7,31]. In 
addition, we have demonstrated that Alendronate can prevent these 
AGEs-induced alterations in osteoblastic function [15]. If our past 
and present in vitro results could be extrapolated to an in vivo setting, 
they could be indicating that Alendronate on one hand opposes the 
deleterious actions of AGEs on osteoblasts, but on the other hand 
potentiates the effects of AGEs on osteoclasts. This duality of action 
of Alendronate on the consequences of AGEs accumulation in bone 
(one of the potential pathogenic mechanisms of diabetic osteopathy) 
is probably the cause of contradictory results that have been found in 
patients with Diabetes mellitus treated with this BP.
In conclusion, we have found that both AGEs and Alendronate 
can inhibit the recruitment and differentiation (TRAP activity) of 
osteoclasts in culture, with an additive effect of both agents at high 
concentrations of Alendronate. While AGEs prevent the early and late 
stages of osteoclastogenesis, Alendronate can only inhibit the latter. 
These results could be indicating a potentiation of the anti-resorptive 
effects of Alendronate when bone extracellular matrix accumulates 
excess AGEs, as occurs in a patient with poorly compensated Diabetes 
mellitus. In addition, AGEs as well as low doses of Alendronate can 
increase the expression of RAGE in osteoclasts, an effect that correlates 
closely with their inhibition of osteoclastogenesis. In cultured 
osteoblasts, AGEs and Alendronate reduce RANKL expression, which 
could also partly explain the inhibitory effects of these agents on the 
recruitment and differentiation of osteoclasts.
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